

STATEMENT OF MEDICAL NECESSITY

The **Oncoguard™ Liver** test is a convenient single blood test that combines analysis of methylated DNA markers and the biomarker alpha fetoprotein with a sophisticated algorithm to help identify hepatocellular carcinoma (HCC) in at-risk patients.

Patient Name: _____ **Patient Date of Birth:** _____

Insurance Payer Name: _____ **Insurance ID:** _____

Ordering Physician Name: _____ **Ordering Physician NPI:** _____

Office Address: _____

Office Phone: _____ **Office Fax:** _____

CPT Code: 81599

Date of Specimen Collection: _____ (MM/DD/YYYY)

ICD-10 Code(s): _____

Symptoms/Clinical Findings:

- | | | |
|---|--|--|
| ☐ Cirrhosis of the liver | ☐ Hepatitis B infection (HBV) | ☐ Fatty liver disease |
| ☐ Other _____ | ☐ Other _____ | ☐ Other _____ |

Prior History (check all the apply):

- | | | |
|--|--|----------------------------------|
| ☐ Hepatitis B infection (HBV) | ☐ Hepatitis C infection (HCV) | ☐ Alcohol |
| ☐ Non-alcoholic fatty liver disease (NAFLD) | ☐ Genetic disorders: _____ | |

Authorized Signature: _____ **Date:** _____

Routine surveillance plays an important role in diagnosing HCC in its early stages and is recommended in AASLD guidelines. This diagnosis is indicative of the patient being at-risk for HCC. To confirm the need for a diagnostic follow-up for potential HCC, it is imperative to perform the Oncoguard Liver test.

AASLD¹

Population:	Cirrhosis and/or HBV (selected)
Surveillance Method(s):	Ultrasound +/- AFP
Frequency:	Every 6 months

1. Heimbach JK, et al. *Hepatology*. 2018;67(1):358-380. AASLD—American Association for the Study of Liver Diseases